Our GLB1 gene dosage studies in Fig. 8A suggest that gene therapy can be a safe and effective treatment for GM1 gangliosidosis, provided that the strength of the promoter driving GLB1 transcription and virus dose is carefully titrated to prevent its overexpression. Here, GLB1 is linked to GM1 gangliosidosis.